Physician profile
David Mulkey
NPI 1396206314
$2,369.75
in general payments reported to CMS, 2019-2025
27 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $438 · 2023: $732 · 2024: $838 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $494.93 | 2023-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $359.93 | 2023-2025 | Xtampza |
| Boston Scientific Corporation | $193.65 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $160.54 | 2022-2025 | |
| Forte Bio-Pharma LLC | $151.69 | 2024 | Prolate, Nalocet |
| Novo Nordisk INC | $116.07 | 2022-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $115.19 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $105.62 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $91.73 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $84.38 | 2022-2023 | Farxiga |
| Exact Sciences Corporation | $62.13 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $57.11 | 2022-2023 | Emgality, Jardiance |
| Indivior INC. | $52.59 | 2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.13 | 2022-2023 | Xifaxan |
| Amgen INC. | $33.58 | 2023 | Repatha |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $32.55 | 2025 | Qutenza |
| Orexo US, INC. | $30.02 | 2024 | Zubsolv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.93 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.32 | 2022 | |
| Antares Pharma, INC. | $23.15 | 2024 | Xyosted |
| Mylan Specialty L.P. | $20.02 | 2023 | Yupelri |
| Protega Pharmaceutials INC | $19.07 | 2025 | Roxybond |
| Biohaven Pharmaceutical Holding Company LTD. | $17.25 | 2022 | |
| Vertos Medical, INC. | $14.60 | 2024 | Mild Device Kit |
| Kowa Pharmaceuticals America, INC. | $14.04 | 2022 | |
| Dexcom, INC. | $13.36 | 2023 | Dexcom G6 Transmitter |
| Tolmar, INC. | $13.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mulkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.